Drug Trial Radar · NCT00146770
Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients
Last checked: Nov 20, 2026Latest source record: Apr 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
May 2001
Primary completion
Mar 2005
Study completion Mar 2005
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- BioMarin/Genzyme LLC
- First posted
- Sep 7, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to collect additional long-term efficacy and safety data of Aldurazyme® (laronidase) patients with MPS I disease. Patients who were previously enrolled in the Phase 3 Double-Blind Study will be enrolled in this study.
Conditions
- Mucopolysaccharidosis I
- Hurler's Syndrome
- Hurler-Scheie Syndrome
- Scheie Syndrome
Interventions
AldurazymeBiological
Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
AldurazymeBiological
0.58 mg/kg Aldurazyme every week for 208 weeks
placeboBiological
Placebo for 26 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 182 in Percent Predicted Forced Vital Capacity (FVC)Time frame: Baseline to Week 182
- Change From Baseline to Week 182 in Six Minute Walk Test (6MWT)Time frame: Baseline to Week 182
Locations
25 sites in 7 countries. Site status is shown where the registry gives one.
University of South Alabama
Mobile, Alabama
Emory University School of Medicine
Atlanta, Georgia
University of Rochester
Rochester, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Toledo Children's Hospital
Toledo, Ohio
Merle West Medical Center
Klamath Falls, Oregon
The Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Hospital Universatario de Universidade Federal de Santa Catarina
Florianópolis, Brazil
Hospital Infantil Joana de Gusmao
Florianópolis, Brazil
Alberta Children's Hospital
Calgary, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
Children's Hospital Klinikum Nord Heidberg
Hamburg, Germany
Medizinishe Hochshule Hannover
Hanover, Germany
Children's Hospital at the University Hospital of Heidelberg
Heidelberg, Germany
Children's Hospital Klinikum der F.S. Universitat
Jena, Germany
Catholic University Sacro Cuore
Rome, Italy
Academisch Ziekenhuis Rotterdam
Rotterdam, Netherlands
Belfast City Hospital
Belfast, United Kingdom
Birmingham Children's Hospital
Birmingham, United Kingdom
Bristol Royal Hospital for Children and Frenchay Hospital
Bristol, United Kingdom
Gartnavel Hospital
Glasgow, United Kingdom
Great Ormond Street Hospital for Sick Children and NHS Trust
London, United Kingdom
Royal Victoria Hospital
Newcastle upon Tyne, United Kingdom
Blackpool Victoria Hospital
Blackpool, Lancashire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.